Vectura, the pharma company specialising in treatments for respiratory diseases, says a trial of one of its development drugs has shown better results than the main competitor.
The not-catchily titled QVA149 is a treatment delivered through an inhaler, mainly targeted at chronic obstructive pulmonary disease - a condition often seen in smokers, or people working in a polluted environment, which can cause debilitating bouts of breathlessness.
The latest study results show a once daily dose of QVA149 gives patients "superior" lung function to the twice daily treatment Seretide.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The drug will now progress to phase III trials in the US, managed by its partner in the project, pharma giant, Novartis.
Vectura shares had gained 4.35% by 10:12.
BS
-
Rail fares to be frozen for first time in 30 years – how much could you save?Chancellor Rachel Reeves will use her Budget to freeze rail fares but the savings could be offset by tax rises
-
Circle sets a new gold standard for cryptocurrenciesCryptocurrencies have existed in a kind of financial Wild West. No longer – they are entering the mainstream, and US-listed Circle is ideally placed to benefit
